Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 168.61M P/E 32.82 EPS this Y -42.20% Ern Qtrly Grth -
Income 8.72M Forward P/E 18.05 EPS next Y -23.10% 50D Avg Chg 6.00%
Sales 219.14M PEG 0.04 EPS past 5Y - 200D Avg Chg 3.00%
Dividend N/A Price/Book 6.52 EPS next 5Y 232.50% 52W High Chg -30.00%
Recommedations 3.00 Quick Ratio 1.20 Shares Outstanding 49.05M 52W Low Chg 74.00%
Insider Own 15.15% ROA 6.02% Shares Float 32.47M Beta 1.08
Inst Own 69.80% ROE 22.10% Shares Shorted/Prior 3.62M/4M Price 3.61
Gross Margin 73.08% Profit Margin 3.98% Avg. Volume 216,567 Target Price -
Oper. Margin -4.63% Earnings Date Oct 31 Volume 122,028 Change 1.69%
About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Puma Biotechnology Inc News
05:38 AM Puma commences Phase II trial of alisertib for breast cancer treatment
11/20/24 Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
11/14/24 We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative
11/09/24 Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations
11/08/24 PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up
11/08/24 Puma Biotechnology Inc (PBYI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ...
11/07/24 Puma Biotech: Q3 Earnings Snapshot
11/07/24 Puma Biotechnology Reports Third Quarter 2024 Financial Results
11/05/24 Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
10/28/24 3 US Penny Stocks With Market Caps Under $700M
10/24/24 Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
10/13/24 With A Return On Equity Of 18%, Has Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Management Done Well?
09/16/24 Puma Biotechnology (NASDAQ:PBYI) investors are sitting on a loss of 79% if they invested five years ago
09/03/24 Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/14/24 Federal Judge Rejects Patent Claims Supporting Puma Biotechnology's Breast Cancer Drug; Company Shares Down After Hours
08/09/24 Puma Biotechnology's (NASDAQ:PBYI) Earnings Offer More Than Meets The Eye
08/04/24 Puma Biotechnology Second Quarter 2024 Earnings: Beats Expectations
08/03/24 Analysts Have Been Trimming Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target After Its Latest Report
08/02/24 Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected
08/02/24 Zacks.com featured highlights Abercrombie & Fitch, Puma Biotechnology, Spotify and Oddity
PBYI Chatroom

User Image Jonnyking Posted - 2 days ago

$PBYI Alan, you need suspend all R&D now and if you have listened to me a couple of years ago, you should have 300m cash on hand and you can collect another 500m to 600m within the next 3-4 years.. an easily 18 dollars a share... time has now changed, the old model will not work. if you keep all spending in 2025-2029 under 40m(only sales force) each year, you can still collect 700m to 800 by end of 2029.... be smart

User Image RealErnFranklin Posted - 4 days ago

$PBYI maybe $1 fills this week $TPET throw a $1 bid too $DRCT , ok .99 bid Everyones doing math on the financials. Banking hard. Nice! $vrar a beauti! 🗞️ socials pump trade idea is $zone , get ur system set up. Play. Dont play. Slap and sell. Get paid. Stop holding tickers

User Image Smilax Posted - 4 days ago

$PBYI going below a dollar. One trick pony with growing operating cost, cost of sales and flat revenue. It is what it is, but may offer a some opportunities before news of phase 2 trial results next year. Still phase 2 doesn’t add revenue and phase 3 can take years.

User Image Jonnyking Posted - 5 days ago

$PBYI going to 0 if trade like this next week, 53 cents off each day, we will be 0 in day 5

User Image PZFLY Posted - 5 days ago

$PBYI This trades at 5 times earnings with 43% revenue growth in the last quarter and today selling of approaching the low of the year. This market is done and fear has set in cancelling out all reason.

User Image Jonnyking Posted - 5 days ago

$PBYI the only positive today was i closed my 2.5cc what will expires today for over 200 dollars gain. we are in way better financial situations now. Alan lay off very aggressively last Q, knock off sga over 40%

User Image Jonnyking Posted - 5 days ago

$PBYI are we going bk? seriously? Alan need start share buy back program and keep lay off, suspend all r&d

User Image Jajhrbdisn Posted - 5 days ago

$PBYI I like this ticket. CEO is a smart guy. I think this will give big returns long term

User Image Cinderella74 Posted - 5 days ago

$PBYI there was a chance after earning.

User Image PSDL75 Posted - 5 days ago

$AKBA is this a healthcare over reaction to RFK? $TGTX $PBYI

User Image Deni_Cain Posted - 5 days ago

$IPHA $PBYI MYNZ Wow, this is insane news! Don't miss out. The train is leaving the station. Add it to your watchlist to see what happens next. 😏

User Image bigpharmaMM Posted - 6 days ago

$PBYI big bulls

User Image PZFLY Posted - 1 week ago

@Biotech2424 $PBYI has my interest. Has fundamentals...actually cheap.

User Image Biotech2424 Posted - 1 week ago

The shorts are getting setup for enormous losses any day now in Coherus. Estimate product revenues for 2025 are $350 million. Market cap at 3.5x forward which is average in industry is $1.15 billion. This sits at $90 million. $CHRS $DRUG $KPTI $PBYI

User Image Biotech2424 Posted - 1 week ago

On a pairs basis $CHRS should equal $1.39 to $PBYI $160 mil market cap.

User Image Biotech2424 Posted - 1 week ago

65 million spread in market cap between $PBYI and $CHRS both had stellar quarters. Puma looking for new assets could be a good marriage here.

User Image bigpharmaMM Posted - 1 week ago

$PBYI bulls

User Image PharmaExpert Posted - 1 week ago

$AKBA, $SYRS, $PBYI, $GOVX, $LPCN 🔥🔥🔥🔥🔥

User Image dnpro Posted - 1 week ago

$PBYI great run together with $BCAB . Now it is missing another partner $SGMT Let's go to new ATH like $BTC.X

User Image Jonnyking Posted - 1 week ago

$PBYI Alan lay off over 35% (about 9m less in SG&A than previous Q, and he should lay off more and bring down the SG&A another 9m lower to 6m and suspend all R&D activity. This will save over 120m each year...

User Image CrytpoConverter Posted - 1 week ago

$PBYI 🔥

User Image Smilax Posted - 1 week ago

$PBYI The company anticipates a higher gross to net adjustment for the full year 2024 due to the impact of the Inflation Reduction Act and unexpected Medicaid rebates. Not good, since IRA may end up being repealed and Medicaid possibly cut next year. Probably isn’t going anywhere soon.

User Image Biotech2424 Posted - 1 week ago

$CHRS Baby Keytruda Buy 100,000 shares and move stock to a cash account. So shorts can’t borrow. I am moving all my stock next week. $350 million revenues in 2025 and trading at normal 3.5x revenues equals upside if trading at 1x sales equals $10.62 stock price. Free $$ and very minimal risk getting back to $1.33 which is same valuation as $PBYI on a market cap basis. $150 million. They have $200 mil revs. Shorts lose $3 million every 10 cents it goes up. At this tiny valuation shorts are paying more in carrying costs - should be covering soon. (Margin, Borrow, missed opportunities) $SMMT $CRBP $ELEV

User Image neofeudal Posted - 1 week ago

$PBYI

User Image ralero Posted - 1 week ago

$PBYI

User Image Biotech2424 Posted - 1 week ago

@2maligators I think everyone thought it might go lower. Now that the low is in the ball will start crushing the shorts the other way. Key don’t get in front of a large rolling stone down a hill. It appears this is the start of a move back up to $1.33 area so basically 50 cents a share of free money here. I am hoping it doesn’t go up to fast honestly since I don’t want to pay capital gains on the money I plan on making until 2026. - $375 million potential revenues 2024 - closest comp I can find is $PBYI and this is multiples better and their market cap is 50% higher (so that’s my free money upside shot to $145 million market cap). So minimum $1.26/$1.33 to compare to PBYI. But they only have one asset. And don’t have capability to go to $375 million revenues ever. So I think we see $1.50 before end of year. Maybe in January. But this is in rally mode now. Don’t let shorts fool you.

User Image Jonnyking Posted - 1 week ago

$PBYI SG&A was 25m last Q, it is 16.8 this Q, almost saved 10m. The $6.2 million decrease in SG&A expenses is because they have lay off almost 25% personnel, knocked it down to 16.8m. They need stop R&D as well. We can see 50m-80m net profit next year based on the current prediction. Alan is doing the right thing, he need lay off more, keep SG&A under 8m, this will save 60m easily each year(net profit) plus 50m of R&D savings, 110m-120m net profit easily. We have reduced debt(22m paid off this q) long term debt was 76.7m last year, same q, now only 32.7m. We will be long-term debt free by next year. Till end of 2029, easily 600m to 800m or 12 to 14 dollars a share.... Alan is actually making the move as I expected. I think he should also announce share buy-back program soon

User Image Jonnyking Posted - 1 week ago

$PBYI Manipulation at its finest. Alan and institution owns probably over 90% shares

User Image PSDL75 Posted - 1 week ago

$PBYI man...back to completely dead

User Image PSDL75 Posted - 1 week ago

$PBYI perfect back test right out the gate..was busy so didn't flip my trading position...dang it

Analyst Ratings
HC Wainwright & Co. Buy Aug 2, 24
HC Wainwright & Co. Buy Jul 26, 24
HC Wainwright & Co. Buy Jun 4, 24
HC Wainwright & Co. Buy Jun 3, 24
HC Wainwright & Co. Buy May 20, 24
HC Wainwright & Co. Buy May 3, 24
HC Wainwright & Co. Buy Mar 1, 24
HC Wainwright & Co. Buy Feb 13, 24
HC Wainwright & Co. Buy Sep 20, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Wong Alvin F Chief Scientific Off.. Chief Scientific Officer Dec 04 Sell 3.7608 280 1,053 97,934 01/10/24
Wong Alvin F Chief Scientific Off.. Chief Scientific Officer Jan 03 Sell 4.4859 7,733 34,689 98,214 01/05/24
Ludwig Jeffrey Jerome Chief Commercial Off.. Chief Commercial Officer Jan 03 Sell 4.4859 12,956 58,119 99,970 01/05/24
AUERBACH ALAN H President and CEO President and CEO Jan 03 Sell 4.4859 41,396 185,698 6,936,947 01/05/24
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Jan 03 Sell 4.4859 15,682 70,348 128,666 01/05/24
HUNT DOUGLAS M See Remarks See Remarks Jan 03 Sell 4.4859 8,358 37,493 103,319 01/05/24
Wong Alvin F Chief Scientific Off.. Chief Scientific Officer Jul 03 Sell 3.3112 6,938 22,973 105,947 07/06/23
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Jul 03 Sell 3.3112 14,680 48,608 144,348 07/06/23
Ludwig Jeffrey Jerome Chief Commercial Off.. Chief Commercial Officer Jul 03 Sell 3.3112 12,103 40,075 112,926 07/06/23
HUNT DOUGLAS M See Remarks See Remarks Jul 03 Sell 3.3112 7,809 25,857 111,677 07/06/23
AUERBACH ALAN H President and CEO President and CEO Jul 03 Sell 3.3112 60,698 200,983 6,978,343 07/06/23
WILSON TROY EDWARD Director Director Jun 13 Sell 3.45 27,000 93,150 350 06/15/23
MOYES JAY M Director Director Jun 13 Sell 3.45 22,000 75,900 16,322 06/15/23
Stuglik Brian M Director Director Jun 13 Sell 3.46 9,900 34,254 31,958 06/15/23
Senderowicz Adrian Director Director Jun 13 Sell 3.45 27,000 93,150 06/15/23
Dorval Allison Director Director Jun 13 Sell 3.45 10,000 34,500 17,000 06/15/23
MILLER MICHAEL PATRICK Director Director Jun 13 Sell 3.45 13,500 46,575 41,358 06/15/23
AUERBACH ALAN H President and CEO President and CEO Jan 03 Sell 4.1779 27,241 113,810 6,852,638 01/05/23
AUERBACH ALAN H President and CEO President and CEO Dec 02 Sell 4.49780 1,251 5,627 6,311,698 12/06/22
HUNT DOUGLAS M See Remarks See Remarks Dec 02 Sell 4.49780 429 1,930 75,575 12/06/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Dec 02 Sell 4.49780 159 715 110,926 12/06/22
Wong Alvin F Chief Scientific Off.. Chief Scientific Officer Dec 02 Sell 4.49780 514 2,312 58,013 12/06/22
HUNT DOUGLAS M See Remarks See Remarks Nov 02 Sell 2.25 429 965 76,004 11/04/22
AUERBACH ALAN H President and CEO President and CEO Nov 02 Sell 2.25 1,242 2,794 6,312,949 11/04/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Nov 02 Sell 2.25 163 367 111,085 11/04/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Oct 03 Sell 2.3354 165 385 111,248 10/05/22
HUNT DOUGLAS M See Remarks See Remarks Oct 03 Sell 2.3354 435 1,016 76,433 10/05/22
AUERBACH ALAN H President and CEO President and CEO Oct 03 Sell 2.3354 1,260 2,943 6,314,191 10/05/22
MILLER MICHAEL PATRICK Director Director Aug 09 Sell 3.5517 25,000 88,792 54,858 08/10/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Aug 02 Sell 2.89 161 465 111,577 08/04/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Jul 05 Sell 2.6315 9,328 24,547 111,738 08/04/22
HUNT DOUGLAS M See Remarks See Remarks Aug 02 Sell 2.89 429 1,240 77,301 08/04/22
AUERBACH ALAN H President and CEO President and CEO Aug 02 Sell 2.89 1,247 3,604 6,316,705 08/04/22
HUNT DOUGLAS M See Remarks See Remarks Jul 05 Sell 2.6315 3,753 9,876 77,730 07/07/22
AUERBACH ALAN H President and CEO President and CEO Jul 05 Sell 2.6315 26,140 68,787 6,317,952 07/07/22
Ludwig Jeffrey Jerome Chief Commercial Off.. Chief Commercial Officer Jul 05 Sell 2.6315 5,835 15,355 64,625 07/07/22
Wong Alvin F Chief Scientific Off.. Chief Scientific Officer Jul 05 Sell 2.6315 2,920 7,684 58,527 07/07/22
Senderowicz Adrian Director Director Jun 16 Sell 2.6313 27,858 73,303 27,000 06/21/22
WILSON TROY EDWARD Director Director Jun 16 Sell 2.5835 27,858 71,971 27,350 06/21/22
Stuglik Brian M Director Director Jun 16 Sell 2.686 13,000 34,918 41,858 06/21/22
MOYES JAY M Director Director Jun 16 Sell 2.6411 22,858 60,370 38,322 06/21/22
Wong Alvin F Chief Scientific Off.. Chief Scientific Officer Jun 02 Sell 1.9241 587 1,129 61,447 06/06/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Jun 02 Sell 1.9218 162 311 121,066 06/06/22
HUNT DOUGLAS M See Remarks See Remarks Jun 02 Sell 1.9441 417 811 81,483 06/06/22
AUERBACH ALAN H President and CEO President and CEO Jun 02 Sell 1.9441 1,200 2,333 6,344,092 06/06/22
HUNT DOUGLAS M See Remarks See Remarks May 03 Sell 2.3101 438 1,012 81,900 05/05/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer May 03 Sell 2.3401 165 386 121,228 05/04/22
AUERBACH ALAN H President and CEO President and CEO May 03 Sell 2.3201 1,263 2,930 6,345,292 05/04/22
AUERBACH ALAN H President and CEO President and CEO Apr 04 Sell 3.078 1,198 3,687 6,346,555 04/05/22
NOUGUES MAXIMO F Chief Financial Offi.. Chief Financial Officer Apr 04 Sell 3.078 206 634 121,393 04/05/22